{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:44:24Z","timestamp":1790729064471,"version":"4.1.0"},"reference-count":40,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Health Science Reports"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>The use of cisplatin in clinical practice in the management of head and neck squamous cell carcinoma (HNSCC) is limited by its toxicity and acquired resistance, which makes the decision\u2010making process of its prescription multifactorial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>An Egyptian expert panel (comprising nine Egyptian oncologists) meeting was held after a comprehensive literature review on the use of cisplatin in HNSCC. The panel aimed to develop a consensus on evidence\u2010based recommendations for receiving cisplatin in the chemoradiotherapy management of HNSCC in Egyptian clinical practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The panel indicated that an Eastern Cooperative Oncology Group Performance Status (ECOG PS)\u2009&gt;\u20092, creatinine clearance (CCR)\u2009&lt;\u200950\u2009ml\/min, neuropathy grade\u2009\u2265\u20092, pre\u2010existing hearing loss or tinnitus \u22652, hematological problems (platelets\u2009&lt;\u2009100,000\/mm<jats:sup>3<\/jats:sup>, neutrophils\u2009&lt;\u20091500\/mm, and hemoglobin\u2009&lt;\u20099\u2009g\/dl), and heart failure of New York Heart Association Classes III or IV (even if cardiovascular therapy is optimized); are all absolute contraindications to receiving cisplatin. On the other hand, relative contraindications to cisplatin according to the panel were an ECOG PS of 2, age more than 70 years, CCR between 50 and 60\u2009ml\/min, grade 1 neuropathy, grade 1 hearing loss, involuntary weight loss of \u226520% of body weight, Child\u2013Pugh Scores B and C, previous induction chemotherapy, and heart failure of New York Heart Association Classes I or II with left ventricular ejection fraction \u226450%. The panel agreed that the socioeconomic status of patients should be considered when prescribing cisplatin to HNSCC patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our discussion resulted in a set of evidence\u2010based recommendations for cisplatin eligibility criteria in patients of HNSCC in Egypt.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hsr2.1037","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T14:40:05Z","timestamp":1674052805000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Eligibility criteria to cisplatin in head and neck squamous cell carcinoma: Egyptian expert opinion"],"prefix":"10.1002","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3856-3290","authenticated-orcid":false,"given":"Mohamed","family":"Abdulla","sequence":"first","affiliation":[{"name":"Department of Oncology, Kasr Al\u2010Aini School of Medicine Cairo University  Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdel Aziz","family":"Belal","sequence":"additional","affiliation":[{"name":"Department of Oncology, Faculty of Medicine Alexandria University  Alexandria Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Sakr","sequence":"additional","affiliation":[{"name":"Department of Oncology, Kasr Al\u2010Aini School of Medicine Cairo University  Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lobna E.","family":"El Arab","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Faculty of Medicine Ain Shams University  Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Mokhtar","sequence":"additional","affiliation":[{"name":"Department of Oncology, Kasr Al\u2010Aini School of Medicine Cairo University  Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasr","family":"Allahloubi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Institute Cairo University  Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramy","family":"Ghali","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Faculty of Medicine Ain Shams University  Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Hashem","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Faculty of Medicine Menoufia University  Menoufia Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed","family":"Arafat","sequence":"additional","affiliation":[{"name":"Department of Oncology, Faculty of Medicine Alexandria University  Alexandria Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,1,18]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2020.105177"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.5041\/RMMJ.10143"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1159\/000357712"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28112"},{"key":"e_1_2_10_7_1","article-title":"Epidemiological trends of head and neck cancer: a population\u2010based study","volume":"2021","author":"Guo K","year":"2021","journal-title":"BioMed Res Int"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/0022034518762071"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coms.2014.01.001"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.4103\/njcp.njcp_310_18"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/0194599819897265"},{"issue":"7","key":"e_1_2_10_12_1","first-page":"1525","article-title":"Quality of life of patients with head and neck cancer: a mixed method study","volume":"14","author":"Nayak SG","year":"2018","journal-title":"J Cancer Res Ther"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2016.12.010"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-013-0260-6"},{"key":"e_1_2_10_15_1","unstructured":"National Comprehensive Cancer Network\u00ae. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae)\u2014Head and\u00a0Neck Cancers. Version 3.2021;2021:1\u2010245."},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2014.07.025"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2018.08.009"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2015.11.019"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-014-2894-9"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.9457"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1159\/000503095"},{"key":"e_1_2_10_22_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2019.00815","article-title":"Best practice in systemic therapy for head and neck squamous cell carcinoma","volume":"9","author":"Oosting SF","year":"2019","journal-title":"Front Oncol"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33283"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/lary.27339"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12323"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-019-01550-6"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0319"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-08-0840"},{"issue":"209","key":"e_1_2_10_29_1","first-page":"292","article-title":"Chemotherapy induced peripheral neuropathy","volume":"35","author":"Kolak A","year":"2013","journal-title":"Pol\u00a0Merkur\u00a0Lekarski"},{"key":"e_1_2_10_30_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2019.01522","article-title":"Treating patients with locally advanced squamous cell carcinoma of the head and neck unsuitable to receive cisplatin\u2010based therapy","volume":"9","author":"Porceddu SV","year":"2020","journal-title":"Front Oncol"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2013.05.006"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0232"},{"key":"e_1_2_10_33_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2019.00464","article-title":"Cisplatin eligibility issues and alternative regimens in locoregionally advanced head and neck cancer: recommendations for clinical practice","volume":"9","author":"Szturz P","year":"2019","journal-title":"Front Oncol"},{"key":"e_1_2_10_34_1","first-page":"1","volume-title":"American Academy Of Audiology Position Statement and Clinical Practice Guidelines: Ototoxicity Monitoring","author":"Durrant JD","year":"2009"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu7010265"},{"key":"e_1_2_10_36_1","unstructured":"WHO; EMRO. WHO EMRO | Programme areas. 2019;(Dec):1\u20102."},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.132.1.32"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx299"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07347-6"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2017.05.063"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-018-01392-9"}],"container-title":["Health Science Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hsr2.1037","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hsr2.1037","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hsr2.1037","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T07:27:47Z","timestamp":1692862067000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hsr2.1037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1002\/hsr2.1037"],"URL":"https:\/\/doi.org\/10.1002\/hsr2.1037","archive":["Portico"],"relation":{},"ISSN":["2398-8835","2398-8835"],"issn-type":[{"value":"2398-8835","type":"print"},{"value":"2398-8835","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"2022-05-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e1037"}}